Cargando…

ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC

Immunotherapy by immune checkpoint inhibitors (ICIs) has showed outstanding efficacy in the treatment of advanced non-small cell lung cancer (NSCLC). The combination of immunotherapy with anti-angiogenic therapy exhibited enhanced efficacy in multiline treatment. However, the potential biomarkers fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yao, Li, Xiaobin, Liu, Guifeng, Chen, Shifu, Xu, Mingyan, Song, Lele, Wang, Yina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509428/
https://www.ncbi.nlm.nih.gov/pubmed/33014846
http://dx.doi.org/10.3389/fonc.2020.01706
_version_ 1783585593734725632
author Chen, Yao
Li, Xiaobin
Liu, Guifeng
Chen, Shifu
Xu, Mingyan
Song, Lele
Wang, Yina
author_facet Chen, Yao
Li, Xiaobin
Liu, Guifeng
Chen, Shifu
Xu, Mingyan
Song, Lele
Wang, Yina
author_sort Chen, Yao
collection PubMed
description Immunotherapy by immune checkpoint inhibitors (ICIs) has showed outstanding efficacy in the treatment of advanced non-small cell lung cancer (NSCLC). The combination of immunotherapy with anti-angiogenic therapy exhibited enhanced efficacy in multiline treatment. However, the potential biomarkers for predicting and monitoring the therapeutic response of the combined therapy remain undefined. In this study, we performed a pilot study by prospectively recruiting 22 advanced NSCLC patients who failed to previous lines of chemotherapy, chemoradiotherapy, TKI therapy, surgery, or any combination of the therapies, and investigated the prognostic factors for patients who received anti-PD-1 (Camrelizumab) and anti-angiogenic (Apatinib) combined therapy. The objective response rate (ORR) assessed by an independent radiology review was 22.7%, and the median progression-free survival (PFS) was 5.25 months. We found that high concentration of circulating-free DNA (cfDNA) (HR = 27.75, P = 0.003), MIKI67 mutation (HR = 114.11, P = 0.009) and gene variations related to hyper-progressive disease (HPD) (HR = 36.85, P = 0.004) were independent risk factors and exhibited significant correlation with PFS. Circulating tumor DNA (ctDNA) mutational status was also a predicting indicator for PFS. In contrast, the blood tumor mutational burden (bTMB) could not stratify the clinical benefit in this combined therapy (HR = 0.81, P = 0.137). Furthermore, we found that the variant allele fraction (VAF) of mutations in ctDNA was sensitive indicators of therapeutic response and therefore can be used to monitor the tumor relief or progression. In conclusion, cfDNA concentration, MIKI67 mutations and HPD-related mutations were independent risk factors and PFS predictors for multiline combined anti-angiogenic/ICI combined therapy. ctDNA may be a novel monitoring biomarker for therapeutic response and predicting biomarker for prognosis in future combined therapy involving PD-1 blockade.
format Online
Article
Text
id pubmed-7509428
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75094282020-10-02 ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC Chen, Yao Li, Xiaobin Liu, Guifeng Chen, Shifu Xu, Mingyan Song, Lele Wang, Yina Front Oncol Oncology Immunotherapy by immune checkpoint inhibitors (ICIs) has showed outstanding efficacy in the treatment of advanced non-small cell lung cancer (NSCLC). The combination of immunotherapy with anti-angiogenic therapy exhibited enhanced efficacy in multiline treatment. However, the potential biomarkers for predicting and monitoring the therapeutic response of the combined therapy remain undefined. In this study, we performed a pilot study by prospectively recruiting 22 advanced NSCLC patients who failed to previous lines of chemotherapy, chemoradiotherapy, TKI therapy, surgery, or any combination of the therapies, and investigated the prognostic factors for patients who received anti-PD-1 (Camrelizumab) and anti-angiogenic (Apatinib) combined therapy. The objective response rate (ORR) assessed by an independent radiology review was 22.7%, and the median progression-free survival (PFS) was 5.25 months. We found that high concentration of circulating-free DNA (cfDNA) (HR = 27.75, P = 0.003), MIKI67 mutation (HR = 114.11, P = 0.009) and gene variations related to hyper-progressive disease (HPD) (HR = 36.85, P = 0.004) were independent risk factors and exhibited significant correlation with PFS. Circulating tumor DNA (ctDNA) mutational status was also a predicting indicator for PFS. In contrast, the blood tumor mutational burden (bTMB) could not stratify the clinical benefit in this combined therapy (HR = 0.81, P = 0.137). Furthermore, we found that the variant allele fraction (VAF) of mutations in ctDNA was sensitive indicators of therapeutic response and therefore can be used to monitor the tumor relief or progression. In conclusion, cfDNA concentration, MIKI67 mutations and HPD-related mutations were independent risk factors and PFS predictors for multiline combined anti-angiogenic/ICI combined therapy. ctDNA may be a novel monitoring biomarker for therapeutic response and predicting biomarker for prognosis in future combined therapy involving PD-1 blockade. Frontiers Media S.A. 2020-09-04 /pmc/articles/PMC7509428/ /pubmed/33014846 http://dx.doi.org/10.3389/fonc.2020.01706 Text en Copyright © 2020 Chen, Li, Liu, Chen, Xu, Song and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chen, Yao
Li, Xiaobin
Liu, Guifeng
Chen, Shifu
Xu, Mingyan
Song, Lele
Wang, Yina
ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC
title ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC
title_full ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC
title_fullStr ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC
title_full_unstemmed ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC
title_short ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC
title_sort ctdna concentration, miki67 mutations and hyper-progressive disease related gene mutations are prognostic markers for camrelizumab and apatinib combined multiline treatment in advanced nsclc
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509428/
https://www.ncbi.nlm.nih.gov/pubmed/33014846
http://dx.doi.org/10.3389/fonc.2020.01706
work_keys_str_mv AT chenyao ctdnaconcentrationmiki67mutationsandhyperprogressivediseaserelatedgenemutationsareprognosticmarkersforcamrelizumabandapatinibcombinedmultilinetreatmentinadvancednsclc
AT lixiaobin ctdnaconcentrationmiki67mutationsandhyperprogressivediseaserelatedgenemutationsareprognosticmarkersforcamrelizumabandapatinibcombinedmultilinetreatmentinadvancednsclc
AT liuguifeng ctdnaconcentrationmiki67mutationsandhyperprogressivediseaserelatedgenemutationsareprognosticmarkersforcamrelizumabandapatinibcombinedmultilinetreatmentinadvancednsclc
AT chenshifu ctdnaconcentrationmiki67mutationsandhyperprogressivediseaserelatedgenemutationsareprognosticmarkersforcamrelizumabandapatinibcombinedmultilinetreatmentinadvancednsclc
AT xumingyan ctdnaconcentrationmiki67mutationsandhyperprogressivediseaserelatedgenemutationsareprognosticmarkersforcamrelizumabandapatinibcombinedmultilinetreatmentinadvancednsclc
AT songlele ctdnaconcentrationmiki67mutationsandhyperprogressivediseaserelatedgenemutationsareprognosticmarkersforcamrelizumabandapatinibcombinedmultilinetreatmentinadvancednsclc
AT wangyina ctdnaconcentrationmiki67mutationsandhyperprogressivediseaserelatedgenemutationsareprognosticmarkersforcamrelizumabandapatinibcombinedmultilinetreatmentinadvancednsclc